To form the evidence base for the Biosimilar Awareness Initiative (the Initiative), the Department procured the University of South Australia (UniSA) to conduct a comprehensive literature search and review.
The Review Authors, Michael Ward, PhD BPharm (Hons), Stephanie Reuter Lange, PhD BSc(Hons) & Kirsten Staff, PhD, MPharm, PGCertEd, conducted a search of all international and Australian clinical, academic and policy journals and other media articles reported in the English language between 1 June 2004 and 28 April 2016.
The primary literature review was published in June 2016. This was subsequently extended with quarterly updates to cover the period July 2016 to June 2018.
The findings of the literature review are used to ensure that the core messages of the Initiative remain relevant in a changing environment.
The issues-based themes below have been used to categorise the literature within the report:
- Determining Access and Subsidisation: Regulatory, Government and Healthcare Provider Biosimilar Medicine Policies to Subsidisation, Switching and Substitution;
- Biosimilar Medicine Uptake: Current Practice of Prescribers, Pharmacists and Patients;
- Adverse Events and Health Outcomes of Biosimilar Medicines (Pharmacovigilance): Impact of Substitution, Switching and Extrapolation of Indication; and
- Evaluating and Improving Stakeholder Biosimilar Awareness, Confidence, Attitudes and Acceptance of Biosimilar Medicine.
You can access the Literature Review:
June 2004 – June 2016
June 2016 – September 2016
September 2016 - December 2016
December 2016 - March 2017
March 2017 - May 2017
June 2017 - August 2017
September 2017 – November 2017
December 2017 - February 2018
March 2018 - May 2018
The March – May 2018 update is the final biosimilars literature review update to be published by the Department. Further evidence reviews will be made available through the Biosimilar Education activities being undertaken by GBMA Education.